These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11565530)

  • 1. Serratia liquefaciens infections at a hemodialysis center.
    Sullivan JD
    N Engl J Med; 2001 Sep; 345(12):922; author reply 922-3. PubMed ID: 11565530
    [No Abstract]   [Full Text] [Related]  

  • 2. Serratia liquefaciens infections at a hemodialysis center.
    DeOreo PB; Kliger AS
    N Engl J Med; 2001 Sep; 345(12):921; author reply 922-3. PubMed ID: 11565529
    [No Abstract]   [Full Text] [Related]  

  • 3. Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center.
    Grohskopf LA; Roth VR; Feikin DR; Arduino MJ; Carson LA; Tokars JI; Holt SC; Jensen BJ; Hoffman RE; Jarvis WR
    N Engl J Med; 2001 May; 344(20):1491-7. PubMed ID: 11357151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serratia liquefaciens infections at a hemodialysis center.
    Kremer K
    N Engl J Med; 2001 Sep; 345(12):922; author reply 922-3. PubMed ID: 11565531
    [No Abstract]   [Full Text] [Related]  

  • 5. Lessons from an epidemic, again.
    Weinstein RA
    N Engl J Med; 2001 May; 344(20):1544-5. PubMed ID: 11357159
    [No Abstract]   [Full Text] [Related]  

  • 6. NN&I's 7th annual survey: the growth game.
    Cooper L
    Nephrol News Issues; 2001 Jul; 15(8):29-30. PubMed ID: 12099227
    [No Abstract]   [Full Text] [Related]  

  • 7. Ownership of dialysis facilities and patients' survival.
    Qunibi WY; Riley DJ; Abboud HE
    N Engl J Med; 2000 Apr; 342(14):1055; author reply 1055-6. PubMed ID: 10755901
    [No Abstract]   [Full Text] [Related]  

  • 8. Do resource utilization and clinical measures still vary across dialysis chains after controlling for the local practices of facilities and physicians?
    Hirth RA; Turenne MN; Wheeler JR; Ma Y; Messana JM
    Med Care; 2010 Aug; 48(8):726-32. PubMed ID: 20613666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMC thrives selling dialysis.
    Kolata GB
    Science; 1980 Apr; 208(4442):379, 381-2. PubMed ID: 7367865
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
    Thamer M; Zhang Y; Kaufman J; Stefanik K; Cotter DJ
    Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Hernán MA
    Am J Kidney Dis; 2007 Oct; 50(4):538-41. PubMed ID: 17900452
    [No Abstract]   [Full Text] [Related]  

  • 12. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a US physician perspective.
    Kasiske BL
    Am J Kidney Dis; 2007 Sep; 50(3):354-7. PubMed ID: 17720512
    [No Abstract]   [Full Text] [Related]  

  • 13. A lesson from the EPO mess: stop the cost shifting.
    Amerling R
    Nephrol News Issues; 2007 Jul; 21(8):52, 54-5, 68. PubMed ID: 17688232
    [No Abstract]   [Full Text] [Related]  

  • 14. Serratia liquefaciens infections at a hemodialysis center.
    Issack MI
    N Engl J Med; 2001 Sep; 345(12):921-2; author reply 922-3. PubMed ID: 11565528
    [No Abstract]   [Full Text] [Related]  

  • 15. Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Aug; 57(32):875-6. PubMed ID: 18701878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic corrections and the potential impact on the dialysis industry.
    Sullivan JD
    Nephrol News Issues; 2009 Jul; 23(8):14-6. PubMed ID: 19662907
    [No Abstract]   [Full Text] [Related]  

  • 17. For-profit status and industry evolution in health care markets: evidence from the dialysis industry.
    Wilson NE
    Int J Health Econ Manag; 2016 Dec; 16(4):297-319. PubMed ID: 27878689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia: dialysis patients experiences.
    Schatell D; Witten B
    Nephrol News Issues; 2004 Nov; 18(12):49-54. PubMed ID: 15595502
    [No Abstract]   [Full Text] [Related]  

  • 19. Ambulatory care centers may find public offerings will be hard to sell.
    Graham J
    Mod Healthc; 1985 Jan; 15(1):112-6. PubMed ID: 10270797
    [No Abstract]   [Full Text] [Related]  

  • 20. Proposed conditions for coverage directed toward dialysis facilities.
    Smetanka S
    Health Care Law Mon; 2005 Apr; ():3-11. PubMed ID: 15895752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.